



2015 LOS ANGELES COUNTY ACUTE CARE HOSPITAL ANTIBIOGRAM DATA

Methodology Notes:

- Data included in the Regional Antibioqram was based on compilation of data from published facility-level antibiograms.
- Facility-level antibiograms that are used to guide empiric therapy of initial infections are generally prepared following CLSI M39 which recommends including data from the first isolate/patient /analysis period. These reports do not include data from subsequent isolates on a patient which may be more resistant than the first isolate. Therefore, % susceptibility data is likely overestimated in some cases.
- Facility-level antibiograms were generally compiled for the calendar year January 1 to December 31.
- Not all facilities reported results for all organism/drug combinations.
- Results are reported as presented by local microbiology labs. Inpatient isolates were used whenever possible, but this could not be determined in some facilities.
- Susceptibility was defined by local labs in all circumstances.
- At least 25% of laboratories submitting data were using outdated breakpoints (higher than currently recommended) for carbapenems in 2015 when testing the gram-negative bacteria listed here. Consequently, %S data for ertapenem and meropenem may be erroneously high.
- For fluoroquinolones, % susceptibility was obtained from both ciprofloxacin and levofloxacin for gram negative pathogens and levofloxacin and moxifloxacin for gram positive agents. The % susceptibility statistic presented is whichever of these two agents revealed the higher value.

Additional Antibioqram Information can be found in “CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 28th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.” And includes:

- Intrinsic resistance profiles of commonly encountered bacteria (Appendix B)
- Cumulative antimicrobial susceptibility report for anaerobic organisms (Appendix D)

Reference:

Clinical and Laboratory Standards Institute (CLSI). 2014. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; M39-A4. CLSI, Wayne, PA